Mark Zucker
Overview
Explore the profile of Mark Zucker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
587
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zucker M, Perry M, Gould S, Elkrief A, Safonov A, Thummalapalli R, et al.
Cell
. 2024 Dec;
188(3):851-867.e17.
PMID: 39701102
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients,...
2.
Eismann L, Zucker M, Dawidek M, Reese S, Calderon L, Aulitzky A, et al.
Urol Pract
. 2024 Jun;
11(5):860-870.
PMID: 38913557
Introduction: Oncological outcomes in patients with nonclear cell renal cell carcinoma (non-ccRCC) treated with surgery for locoregional nodal disease (ND) remain incompletely characterized. The objective was to investigate the characteristics...
3.
Kotecha R, Doshi S, Knezevic A, Chaim J, Chen Y, Jacobi R, et al.
Eur Urol Oncol
. 2023 Nov;
7(4):804-811.
PMID: 37945488
Background: Although different kidney cancers represent a heterogeneous group of malignancies, multiple subtypes including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient...
4.
Tourigny D, Zucker M, Kim M, Russo P, Coleman J, Lee C, et al.
Front Oncol
. 2022 Jul;
12:910147.
PMID: 35837094
Renal medullary carcinoma (RMC) is a highly aggressive disease associated with sickle hemoglobinopathies and universal loss of the tumor suppressor gene . RMC has a relatively low rate of incidence...
5.
Lee C, Voss M, Carlo M, Chen Y, Zucker M, Knezevic A, et al.
J Clin Oncol
. 2022 Mar;
40(21):2333-2341.
PMID: 35298296
Purpose: To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell renal cell carcinoma (RCC). Patients And Methods: Patients had advanced...
6.
Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale R, Rappold P, et al.
Eur Urol Focus
. 2022 Mar;
8(5):1278-1288.
PMID: 35288096
Background: Succinate dehydrogenase-deficient and fumarate hydratase-deficient renal cell carcinomas (SDHRCC and FHRCC) are rare kidney cancers driven by loss of TCA cycle enzymes. Objective: To define and compare the genomic...
7.
Symer D, Akagi K, Geiger H, Song Y, Li G, Emde A, et al.
Genome Res
. 2021 Dec;
32(1):55-70.
PMID: 34903527
Human papillomavirus (HPV) causes 5% of all cancers and frequently integrates into host chromosomes. The HPV oncoproteins E6 and E7 are necessary but insufficient for cancer formation, indicating that additional...
8.
Gleeson J, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, et al.
Clin Cancer Res
. 2021 Mar;
27(10):2910-2919.
PMID: 33658299
Purpose: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive form of RCC associated with hereditary leiomyomatosis and RCC syndrome. Evidence for systemic therapy efficacy is lacking. Experimental Design:...
9.
Okoh A, Chan O, Schultheis M, Fugar S, Kang N, Kaplon S, et al.
Innovations (Phila)
. 2019 May;
14(3):236-242.
PMID: 31050325
Objective: We sought to investigate outcomes after left ventricular assist device (LVAD) implantation in advanced heart failure patients stratified by race. Methods: Patients who had LVADs inserted at a single...
10.
Gillison M, Akagi K, Xiao W, Jiang B, Pickard R, Li J, et al.
Genome Res
. 2018 Dec;
29(1):1-17.
PMID: 30563911
Human papillomavirus (HPV) is a necessary but insufficient cause of a subset of oral squamous cell carcinomas (OSCCs) that is increasing markedly in frequency. To identify contributory, secondary genetic alterations...